Stool Transplant in Treating Recurrent or Refractory C. Difficile Infection in Patients with Solid Tumors

Inclusion Criteria

• Patients with solid organ malignancy who have received chemotherapy within the past six months
• Clinical and microbiologic relapse of C. difficile associated diarrhea after at least one course of adequate antibiotic therapy or refractory disease that does not respond to treatment * At least 10 days of vancomycin at least 125 mg four times daily (QID), or metronidazole 500 mg three times daily (TID) * C. difficile associated diarrhea is defined as: ** >= 3 loose or watery stools per day for at least 2 consecutive days or >= 8 loose stools in 48 hours and ** Positive Clostridium difficile polymerase chain reaction (PCR)
• Life expectancy of > 3 months

Exclusion Criteria

• Human immunodeficiency virus (HIV) infection with CD4 count < 240
• History of hematopoietic stem cell transplant (HSCT)
• Hematologic malignancy
• Absolute neutrophil count (ANC) < 1000/mm^3
• Serious cardiopulmonary comorbidities
• Inability to tolerate anesthesia
• Hemoglobin (HGB) < 8 g/dL
• Platelets (PLT) < 50,000 K/mcL
• International normalized ratio (INR) > 1.5 INR
• Pregnant patients will be excluded from this study
• Inflammatory bowel disease
• Active fistula
• Small bowel obstruction
• Ileus
• Gastroparesis
• Nausea and vomiting
• Gastrointestinal surgery within the previous 3 months